Zydus receives final approval from the USFDA for Febuxostat Tablets

Zydus receives final approval from the USFDA for Febuxostat Tablets

The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India.

FPJ Web DeskUpdated: Tuesday, January 10, 2023, 03:14 PM IST
article-image
Zydus receives final approval from the USFDA for Febuxostat Tablets | File/ Representative image

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Febuxostat Tablets, 40 mg and 80 mg (USRLD: Uloric Tablets).

Febuxostat tablets are indicated to lower hyperuricemia (high uric acid in the blood) in patients with gout who have been treated with allopurinol that did not work well or cannot be treated with allopurinol. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India.

Febuxostat tablets had annual sales of USD 32 million in the United States according to IQVIA data (IQVIA MAT Sept. 2022).

The group now has 340 approvals and has so far filed over 431* ANDAs since the commencement of the filing process in FY 2003-04.

(To receive our E-paper on WhatsApp daily, please click here.  To receive it on Telegram, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

RECENT STORIES

Participation of women in workplaces with hybrid models found to be higher

Participation of women in workplaces with hybrid models found to be higher

SCHOTT enters PPA with CleanMax for wind solar hybrid project

SCHOTT enters PPA with CleanMax for wind solar hybrid project

Maiden Forgings IPO opens on March 23

Maiden Forgings IPO opens on March 23

PNB Scam: Interpol’s decision to remove Mehul Choksi from Red Corner Notice ‘faulty’

PNB Scam: Interpol’s decision to remove Mehul Choksi from Red Corner Notice ‘faulty’

Mastek Vice-Chairman Ashank Desai to become Non-Executive Chairman from April

Mastek Vice-Chairman Ashank Desai to become Non-Executive Chairman from April